The Naval Medical Logistics Command intends to establish, on a sole source basis in accordance with FAR 13.501(a), a research and development contract with GenVec, Inc. as the only source that can facilitate a phase 1 clinical trial of a tetravalent dengue vaccine based on replication defective, recombinant adenovirus vector platform for the Naval Medical Research Center in Silver Spring, MD. The intended procurement will be classified under North American Industry Classification System (NAICS) 325414 with a Small Business Size Standard of 500 employees. There is no set aside for this procurement. This notice is not a request for competitive proposals. However, parties interested in responding to this notice will need to submit technical data sufficient to determine capability in providing the same product. All capability statements received within by the closing date will be considered by the Government. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Responses shall contain sufficient documentation to establish a bonafied capability to fulfill the requirements. All inquiries must be emailed to [email protected] by the response date. No Phone calls will be accepted

Bid Protests Not Available